| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.1129594 |
| P698 | PubMed publication ID | 16888140 |
| P50 | author | Jeffrey Ravetch | Q1359564 |
| Falk Nimmerjahn | Q1394084 | ||
| P2093 | author name string | Yoshikatsu Kaneko | |
| P2860 | cites work | Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity | Q30835165 |
| P433 | issue | 5787 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| P1104 | number of pages | 4 | |
| P304 | page(s) | 670-673 | |
| P577 | publication date | 2006-08-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation | |
| P478 | volume | 313 |
| Q38820352 | 10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders |
| Q83232977 | 9 Human Immunoglobulins |
| Q43239608 | A bone to pick with Fc gamma receptors |
| Q36008257 | A common glycan structure on immunoglobulin G for enhancement of effector functions |
| Q92864490 | A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity |
| Q46242617 | A framework for real-time glycosylation monitoring (RT-GM) in mammalian cell culture |
| Q45411008 | A mechanism of sialylation functionally silences the hyaluronan receptor LYVE-1 in lymphatic endothelium. |
| Q41701035 | A method to identify trace sulfated IgG N-glycans as biomarkers for rheumatoid arthritis. |
| Q51088233 | A novel pathogenesis of inflammatory bowel disease from the perspective of glyco-immunology. |
| Q37756017 | A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. |
| Q26827579 | A perspective on the structure and receptor binding properties of immunoglobulin G Fc |
| Q30368704 | A pilot study showing differences in glycosylation patterns of IgG subclasses induced by pneumococcal, meningococcal, and two types of influenza vaccines. |
| Q33411528 | A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy |
| Q64262117 | A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity |
| Q30498394 | A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples |
| Q41639511 | A simultaneous assessment metric for MAb quantity and glycan quality. |
| Q79222449 | A sugar switch for anti-inflammatory antibodies |
| Q37283979 | A surface-exposed neuraminidase affects complement resistance and virulence of the oral spirochaete Treponema denticola |
| Q35762130 | A systematic study of glycopeptide esterification for the semi-quantitative determination of sialylation in antibodies |
| Q90461272 | Abberant Immunoglobulin G Glycosylation in Rheumatoid Arthritis by LTQ-ESI-MS |
| Q36950893 | Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients |
| Q38976135 | Aberrant serum immunoglobulin G glycosylation in chronic hepatitis B is associated with histological liver damage and reversible by antiviral therapy |
| Q37378334 | Absolute quantitation of immunoglobulin G and its glycoforms using multiple reaction monitoring. |
| Q42963600 | Activating and inhibitory Fc gamma receptors in rheumatoid arthritis: from treatment to targeted therapies |
| Q36657882 | Activating and inhibitory FcgammaRs in autoimmune disorders. |
| Q57583344 | Activating and inhibitory Fcγ receptors in immunotherapy: being the actor or being the target |
| Q37104028 | Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling |
| Q39726192 | Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition |
| Q39197881 | Advances in analytical methodologies to guide bioprocess engineering for bio-therapeutics. |
| Q37676032 | Advances in diagnosing and managing antibody-mediated rejection |
| Q38544529 | Advances in pharmacotherapy to treat kidney transplant rejection |
| Q34065598 | Advances in the use of biologic agents for the treatment of systemic vasculitis |
| Q55116109 | Affinity of human IgG subclasses to mouse Fc gamma receptors. |
| Q35850207 | Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. |
| Q34529388 | Agglutination of Histoplasma capsulatum by IgG monoclonal antibodies against Hsp60 impacts macrophage effector functions |
| Q37068434 | Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors |
| Q34764161 | Altered functionality of anti-bacterial antibodies in patients with chronic hepatitis C virus infection |
| Q48138068 | Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy. |
| Q33305767 | Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool |
| Q38074384 | An 'omics approach towards CHO cell engineering. |
| Q94465707 | An Engineered Pathway for Production of Terminally Sialylated N-glycoproteins in the Periplasm of Escherichia coli |
| Q38546315 | An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus |
| Q51428039 | An exploratory trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis: a preliminary multicenter report. |
| Q34084985 | An innovative approach for the characterization of the isoforms of a monoclonal antibody product |
| Q28728886 | Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation |
| Q49129602 | Analysis of gamma-globulin mobility on routine clinical CE equipment: exploring its molecular basis and potential clinical utility |
| Q33903461 | Analytical and Functional Aspects of Antibody Sialylation. |
| Q52669512 | Analytical comparability study of recombinant monoclonal antibody therapeutics. |
| Q36651493 | Analytical glycobiology at high sensitivity: current approaches and directions |
| Q36125875 | Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy |
| Q55178105 | Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange |
| Q35590968 | Anti-aβ oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment |
| Q58234756 | Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis |
| Q53445087 | Anti-citrullinated-protein-antibody-specific intravenous immunoglobulin attenuates collagen-induced arthritis in mice. |
| Q34199547 | Anti-inflammatory IgG production requires functional P1 promoter in β-galactoside α2,6-sialyltransferase 1 (ST6Gal-1) gene |
| Q84549496 | Anti-inflammatory activity of sublingual immunoglobulin (SLIG) in a murine model of allergen-driven airway inflammation |
| Q30417917 | Anti-inflammatory immune skewing is atheroprotective: Apoe−/−FcγRIIb−/− mice develop fibrous carotid plaques |
| Q88250876 | Anti-inflammatory intravenous immunoglobulin (IVIg) suppresses homeostatic proliferation of B cells |
| Q37311301 | Anti-rhesus D prophylaxis in pregnant women is based on sialylated IgG antibodies |
| Q90681771 | Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis |
| Q37015487 | Antibodies and their receptors: different potential roles in mucosal defense. |
| Q36960241 | Antibodies to citrullinated proteins: pathogenic and diagnostic significance |
| Q46348633 | Antibody blood-brain barrier efflux is modulated by glycan modification |
| Q35116554 | Antibody effector functions mediated by Fcγ-receptors are compromised during persistent viral infection |
| Q55162053 | Antibody receptors steal the sweet spotlight. |
| Q30408097 | Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies |
| Q38103583 | Antibody-based therapy in colorectal cancer |
| Q36718541 | Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis |
| Q37990988 | Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale |
| Q50540781 | Antibody-mediated sialidase activity in blood serum of patients with multiple myeloma. |
| Q30616406 | Antibody-mediated trapping of helminth larvae requires CD11b and Fcγ receptor I. |
| Q27687250 | Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases |
| Q36239724 | Arthrobacter endo-beta-N-acetylglucosaminidase shows transglycosylation activity on complex-type N-glycan oxazolines: one-pot conversion of ribonuclease B to sialylated ribonuclease C. |
| Q88500183 | Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcγR Types |
| Q92458090 | Assessment of serum sialic acid correlated with C3 in children with Mycoplasma pneumoniae pneumonia |
| Q50098437 | Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study |
| Q40368570 | Association of Fcgamma receptor type 2A and 3A genotypes with rheumatoid arthritis in Chinese population |
| Q36225198 | Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome |
| Q36517187 | At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody |
| Q41762205 | Autoantibodies targeting tumor-associated antigens in metastatic cancer: Sialylated IgGs as candidate anti-inflammatory antibodies |
| Q36821512 | Autoimmunity in systemic sclerosis: current concepts |
| Q35729131 | Autoreactivity in human IgG+ memory B cells |
| Q33403107 | B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo |
| Q37308252 | B cells and immunological tolerance. |
| Q35840324 | B cells in cardiac transplants: from clinical questions to experimental models |
| Q26771404 | B cells with regulatory properties in transplantation tolerance |
| Q38168787 | B-cell modulation of dendritic-cell function: signals from the far side |
| Q37065114 | B-cell-independent sialylation of IgG. |
| Q24651567 | Beyond CA125: the coming of age of ovarian cancer biomarkers |
| Q92922026 | Biological Functions and Analytical Strategies of Sialic Acids in Tumor |
| Q38593977 | Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts |
| Q37291380 | Boronic Acid-based approach for separation and immobilization of glycoproteins and its application in sensing |
| Q42583191 | Branch-specific sialylation of IgG-Fc glycans by ST6Gal-I. |
| Q57253418 | Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo |
| Q39276137 | CHO-gmt5, a novel CHO glycosylation mutant for producing afucosylated and asialylated recombinant antibodies |
| Q91386762 | Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells |
| Q83412093 | Carbohydrate dynamics: Antibody glycans wiggle and jiggle |
| Q35654967 | Carboxybetaine Modified Interface for Electrochemical Glycoprofiling of Antibodies Isolated from Human Serum. |
| Q36755919 | Cells of the synovium in rheumatoid arthritis. B cells |
| Q26773052 | Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs |
| Q34772586 | Change in IgG1 Fc N-linked glycosylation in human lung cancer: age- and sex-related diagnostic potential |
| Q37629724 | Changes in IgG and total plasma protein glycomes in acute systemic inflammation |
| Q55510375 | Changes in N-glycans of IgG4 and its relationship with the existence of hypocomplementemia and individual organ involvement in patients with IgG4-related disease. |
| Q35878770 | Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination |
| Q99564880 | Changes in subclass-specific IgG Fc glycosylation associated with the postnatal maturation of the murine immune system |
| Q37597698 | Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. |
| Q90596112 | Characterization of Endogenous Human FcγRIII by Mass Spectrometry Reveals Site, Allele and Sequence Specific Glycosylation |
| Q58276816 | Characterization of Minor N-linked Glycans on Antibodies Using Endo H Release and MALDI–Mass Spectrometry |
| Q39782184 | Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody |
| Q37581781 | Chemical and chemoenzymatic synthesis of glycoproteins for deciphering functions |
| Q38863037 | Chemically synthesized glycoconjugates on proteins: effects of multivalency and glycoform in vivo |
| Q39061546 | Chemoenzymatic Fc glycosylation via engineered aldehyde tags. |
| Q36852736 | Chemoenzymatic Glyco-engineering of Monoclonal Antibodies |
| Q36189447 | Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. |
| Q35555990 | Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor |
| Q37468164 | Chemoenzymatic synthesis and lectin array characterization of a class of N-glycan clusters. |
| Q47874093 | Chemoenzymatic synthesis of glycoengineered IgG antibodies and glycosite-specific antibody-drug conjugates. |
| Q28384089 | Chronic inflammatory demyelinating polyneuropathy |
| Q38820288 | Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations |
| Q41622831 | Clinical severity of visceral leishmaniasis is associated with changes in immunoglobulin g fc N-glycosylation |
| Q30886916 | Combination of IgG N-glycomics and corresponding transcriptomics data to identify anti-TNF-α treatment responders in inflammatory diseases |
| Q28820826 | Comparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc Glycoforms |
| Q41512058 | Comparative N-Glycosylation Analysis of the Fc Portions of a Chimeric Human Coagulation Factor VIII and Immunoglobulin G1 |
| Q89984919 | Comparing different domains of analysis for the characterisation of N-glycans on monoclonal antibodies |
| Q35803387 | Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G |
| Q36216323 | Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles--part 1: separation-based methods |
| Q36554708 | Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G |
| Q55050150 | Complement in the Initiation and Evolution of Rheumatoid Arthritis. |
| Q37679726 | Complex genetic regulation of protein glycosylation |
| Q57471354 | Comprehensive analysis of N-glycans in IgG purified from ferrets with or without influenza A virus infection |
| Q42933039 | Conference report: "Functional Glycomics in HIV Type 1 Vaccine Design" workshop report, Bethesda, Maryland, April 30-May 1, 2012. |
| Q64101963 | Contribution of Fcγ Receptor-Mediated Immunity to the Pathogenesis Caused by the Human Respiratory Syncytial Virus |
| Q33420853 | Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity |
| Q47656437 | Controlling the time evolution of mAb N-linked glycosylation, Part I: Microbioreactor experiments. |
| Q94539926 | Convalescent plasma in Covid-19: Possible mechanisms of action |
| Q57676590 | Coupling porous sheathless interface MS with transient-ITP in neutral capillaries for improved sensitivity in glycopeptide analysis |
| Q27674690 | Crystal Structure of Fc Receptor I and Its Implication in High Affinity -Immunoglobulin Binding |
| Q44852748 | Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development |
| Q36484383 | Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis |
| Q34620111 | Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies |
| Q33415298 | Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain |
| Q36787544 | Cytokine storm in a mouse model of IgG-mediated hemolytic transfusion reactions. |
| Q42185658 | DC-SIGN gene promoter variants and IVIG treatment response in Kawasaki disease |
| Q40077073 | Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities |
| Q35991588 | Deregulated Fcγ receptor expression in patients with CIDP. |
| Q48222733 | Designer α1,6-Fucosidase Mutants Enable Direct Core Fucosylation of Intact N-Glycopeptides and N-Glycoproteins. |
| Q55021130 | Development of Two Analytical Methods Based on Reverse Phase Chromatographic and SDS-PAGE Gel for Assessment of Deglycosylation Yield in N-Glycan Mapping. |
| Q38478867 | Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye. |
| Q39709073 | Differences in N-glycan structures found on recombinant IgA1 and IgA2 produced in murine myeloma and CHO cell lines |
| Q31082369 | Differences in neural-immune gene expression response in rat spinal dorsal horn correlates with variations in electroacupuncture analgesia |
| Q34258085 | Different IVIG glycoforms affect in vitro inhibition of anti-ganglioside antibody-mediated complement deposition |
| Q30428210 | Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines |
| Q47804590 | Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity? |
| Q56169018 | Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death |
| Q30830469 | Direct identification of nonreducing GlcNAc residues on N-glycans of glycoproteins using a novel chemoenzymatic method |
| Q36016305 | Disease-specific IgG Fc N-glycosylation as personalized biomarkers to differentiate gastric cancer from benign gastric diseases |
| Q90723253 | Disruption of hepatocyte Sialylation drives a T cell-dependent pro-inflammatory immune tone |
| Q38587703 | Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach. |
| Q53313488 | Diversification of IgG effector functions. |
| Q36950370 | Dominant suppression of inflammation by glycan-hydrolyzed IgG |
| Q41819438 | Dose-dependent inhibition of demyelination and microglia activation by IVIG. |
| Q33736332 | Dual role for Fcγ receptors in host defense and disease in Borrelia burgdorferi-infected mice |
| Q33520919 | Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation |
| Q93102873 | Early Stage Glycosylation Biomarkers in Alzheimer's Disease |
| Q64084591 | Editorial: Autoantibodies |
| Q36484438 | Efficacy of Intravenous Immunoglobulin in Neurological Diseases. |
| Q36903911 | Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers |
| Q38847934 | Electrochemical lectin based biosensors as a label-free tool in glycomics. |
| Q51321746 | Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors. |
| Q33439789 | Emerging drugs for immune thrombocytopenia (ITP). |
| Q64903536 | Emerging glycobiology tools: A renaissance in accessibility. |
| Q90496015 | Emerging immunotherapies for autoimmune kidney disease |
| Q37417435 | Emerging methods for the production of homogeneous human glycoproteins |
| Q34676070 | Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function |
| Q35685635 | Emerging technologies for making glycan-defined glycoproteins |
| Q57253528 | Endoglycosidase treatment abrogates IgG arthritogenicity: Importance of IgG glycosylation in arthritis |
| Q26766715 | Engineered IgG1-Fc--one fragment to bind them all |
| Q47220975 | Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease |
| Q38697625 | Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs. |
| Q27678524 | Engineering Hydrophobic Protein–Carbohydrate Interactions to Fine-Tune Monoclonal Antibodies |
| Q33661333 | Engineering host cell lines to reduce terminal sialylation of secreted antibodies |
| Q37730868 | Engineering mammalian cells in bioprocessing - current achievements and future perspectives |
| Q38328602 | Engineering novel Lec1 glycosylation mutants in CHO-DUKX cells: molecular insights and effector modulation of N-acetylglucosaminyltransferase I. |
| Q91741458 | Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease |
| Q37245752 | Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16 |
| Q89992520 | Enhancement of sialylation in rIgG in glyco-engineered Chinese hamster ovary cells |
| Q38329171 | Enhancement of sialylation on humanized IgG-like bispecific antibody by overexpression of α2,6-sialyltransferase derived from Chinese hamster ovary cells. |
| Q38827936 | Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells |
| Q47190029 | Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands |
| Q33396115 | Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia |
| Q37646832 | Estrogens regulate glycosylation of IgG in women and men |
| Q42580265 | European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK |
| Q35624937 | Evidence that FcRn mediates the transplacental passage of maternal IgE in the form of IgG anti-IgE/IgE immune complexes |
| Q38320800 | Evidence that calf bronchopneumonia may be accompanied by increased sialylation of circulating immune complexes' IgG. |
| Q89186707 | Evolution of sialic acids: Implications in xenotransplant biology |
| Q26779027 | Exploiting natural anti-carbohydrate antibodies for therapeutic purposes |
| Q90222396 | Exploration of the Sialic Acid World |
| Q38776111 | Exploring the glycan interaction in vivo: Future prospects of neo-glycoproteins for diagnostics. |
| Q98466537 | Expression Profiling and Glycan Engineering of IgG Subclass 1-4 in Nicotiana benthamiana |
| Q51002069 | Expression and function of the inhibitory Fcγ-receptor in CIDP. |
| Q30412932 | Expression and glycoengineering of functionally active heteromultimeric IgM in plants |
| Q34427307 | Expressional analysis of immunoglobulin D in cattle (Bos taurus), a large domesticated ungulate |
| Q64079585 | Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine |
| Q35003386 | Fab fragment glycosylated IgG may play a central role in placental immune evasion |
| Q89770401 | Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIa |
| Q28076303 | Fc gamma receptors: glycobiology and therapeutic prospects |
| Q38206710 | Fc glycan-modulated immunoglobulin G effector functions. |
| Q26799266 | Fc glycans of therapeutic antibodies as critical quality attributes |
| Q37998314 | Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond |
| Q26783175 | Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases |
| Q49369660 | Fc-Glycosylation in Human IgG1 and IgG3 Is Similar for Both Total and Anti-Red-Blood Cell Anti-K Antibodies |
| Q90484391 | Fc-Linked IgG N-Glycosylation in FcγR Knock-Out Mice |
| Q64060972 | Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease |
| Q26822421 | Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics |
| Q34994340 | Fc-glycosylation of IgG1 is modulated by B-cell stimuli |
| Q36991445 | Fc-receptors as regulators of immunity. |
| Q29615584 | Fcgamma receptors as regulators of immune responses |
| Q36922979 | FcgammaRIIB as a modulator of autoimmune disease susceptibility |
| Q37736263 | FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. |
| Q47945550 | Fcγ Receptor Function and the Design of Vaccination Strategies |
| Q39217862 | Fcγ Receptor Heterogeneity in Leukocyte Functional Responses. |
| Q33438855 | Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia. |
| Q38615357 | Fcγ receptor pathways during active and passive immunization |
| Q30981881 | FcγRIIB and autoimmunity |
| Q38239285 | FcγRIIB as a key determinant of agonistic antibody efficacy |
| Q37990547 | FcγRIIB: a modulator of cell activation and humoral tolerance. |
| Q34757115 | Fetal intraperitoneal injection of immunoglobulin diminishes alloimmune hemolysis |
| Q43692759 | Filariasis asymptomatically infected donors have lower levels of disialylated IgG compared to endemic normals |
| Q43696832 | Fine-tuning the specificity of boronate affinity monoliths toward glycoproteins through pH manipulation |
| Q37327690 | Fractionation of Fab glycosylated immunoglobulin G with concanavalin A chromatography unveils new structural properties of the molecule |
| Q52597179 | Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy. |
| Q59813339 | Fucosyl-Agalactosyl IgG₁ Induces Cholangiocarcinoma Metastasis and Early Recurrence by Activating Tumor-Associated Macrophage |
| Q33402880 | Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice |
| Q88500050 | GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role for IL-11 cannot be ruled out |
| Q35623058 | GPQuest: A Spectral Library Matching Algorithm for Site-Specific Assignment of Tandem Mass Spectra to Intact N-glycopeptides. |
| Q42069958 | Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis |
| Q34589283 | Galactosyltransferase 4 is a major control point for glycan branching in N-linked glycosylation |
| Q36932153 | General mechanism for modulating immunoglobulin effector function |
| Q42725794 | Generation of a Mutant Mucor hiemalis Endoglycosidase That Acts on Core-fucosylated N-Glycans. |
| Q52688333 | Generation of efficient mutants of endoglycosidase from Streptococcus pyogenes and their application in a novel one-pot transglycosylation reaction for antibody modification. |
| Q38204889 | Genetic characteristics and pathogenic mechanisms of periodontal pathogens |
| Q36179265 | Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants. |
| Q30363360 | Glycans - the third revolution in evolution. |
| Q34292392 | Glycans in sera of amyotrophic lateral sclerosis patients and their role in killing neuronal cells |
| Q26782025 | Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review |
| Q38034471 | Glyco-engineering in plants to produce human-like N-glycan structures |
| Q38028654 | GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins |
| Q37448685 | Glycobiology of immune responses |
| Q35705039 | Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities |
| Q37066000 | Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation |
| Q35736606 | Glycome characterization of immunoglobulin G from buffalo (Bubalus bubalis) colostrum |
| Q45097248 | Glycomic profiling of glycoproteins |
| Q35003989 | Glycomic signatures on serum IgGs for prediction of postvaccination response |
| Q36742404 | Glycoproteomic analysis of antibodies |
| Q89621283 | Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid |
| Q36624721 | Glycosylation Profile of IgG in Moderate Kidney Dysfunction |
| Q37402407 | Glycosylation as a strategy to improve antibody-based therapeutics |
| Q39361301 | Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. |
| Q46813097 | Glycosylation of IgG B cell receptor (IgG BCR) in multiple myeloma: relationship between sialylation and the signal activity of IgG BCR. |
| Q50138178 | Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases |
| Q35311994 | Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss |
| Q26745510 | Glycosylation of matrix metalloproteases and tissue inhibitors: present state, challenges and opportunities |
| Q38807919 | Glycosylation of monoclonal antibody products: Current status and future prospects |
| Q33431066 | Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia |
| Q35129041 | Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies |
| Q37287652 | Glycosylation profiles of epitope-specific anti-beta-amyloid antibodies revealed by liquid chromatography-mass spectrometry |
| Q38126913 | Glycosylation: impact, control and improvement during therapeutic protein production. |
| Q41941555 | Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling |
| Q27027997 | Glycotherapy: new advances inspire a reemergence of glycans in medicine |
| Q90455147 | Going Native: Synthesis of Glycoproteins and Glycopeptides via Native Linkages To Study Glycan-Specific Roles in the Immune System |
| Q37683571 | Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance. |
| Q60921468 | High accuracy differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma by immunoglobulin G glycosylation |
| Q39604919 | High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. |
| Q35497686 | High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations |
| Q93062532 | High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease |
| Q98224836 | High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects |
| Q37532013 | High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases |
| Q47567099 | High-dose intravenous immunoglobulins for the treatment of dermatological autoimmune diseases |
| Q41185651 | High-resolution physicochemical characterization of different intravenous immunoglobulin products |
| Q37712517 | High-sensitivity analytical approaches for the structural characterization of glycoproteins |
| Q38797703 | High-throughput analysis of immunoglobulin G glycosylation |
| Q39446586 | High-throughput analysis of intraclonal variability of glycoprotein sialylation |
| Q45945255 | High-throughput characterization of the functional impact of IgG Fc glycan aberrancy in juvenile idiopathic arthritis. |
| Q35019925 | High-throughput glycosylation analysis of therapeutic immunoglobulin G by capillary gel electrophoresis using a DNA analyzer |
| Q64069939 | Highly Variable Sialylation Status of Donor-Specific Antibodies Does Not Impact Humoral Rejection Outcomes |
| Q38953491 | Highly individual patterns of virus-immune IgG effector responses in humans |
| Q35583369 | Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3). |
| Q49932309 | Hochdosierte intravenöse Immunglobuline bei dermatologischen Autoimmunerkrankungen |
| Q92605184 | Homogeneous production and characterization of recombinant N-GlcNAc-protein in Pichia pastoris |
| Q92106772 | How Autoantibodies Regulate Osteoclast Induced Bone Loss in Rheumatoid Arthritis |
| Q37035334 | How many ways through the Golgi maze? |
| Q91776771 | Human DC-SIGN and CD23 do not interact with human IgG |
| Q39160831 | Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors |
| Q28471918 | Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis |
| Q26779758 | Human IgG4: a structural perspective |
| Q41203183 | Human Retrotransposon Insertion Polymorphisms Are Associated with Health and Disease via Gene Regulatory Phenotypes |
| Q36210573 | Human schistosome infection and allergic sensitisation |
| Q52807572 | Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity. |
| Q36245665 | Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis |
| Q50088056 | Hyposialylated IgG activates endothelial IgG receptor FcγRIIB to promote obesity-induced insulin resistance |
| Q33683531 | IVIG regulates the survival of human but not mouse neutrophils |
| Q38699812 | IVIG-mediated effector functions in autoimmune and inflammatory diseases |
| Q33399346 | IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. |
| Q37018736 | Identification of a receptor required for the anti-inflammatory activity of IVIG. |
| Q46978895 | Identification of manipulated variables for a glycosylation control strategy |
| Q36946538 | Identification of novel plasma glycosylation-associated markers of aging |
| Q92027568 | IgE Glycosylation in Health and Disease |
| Q28510454 | IgEb immune complexes activate macrophages through FcgammaRIV binding |
| Q61813265 | IgG Fc Glycosylation Patterns of Preterm Infants Differ With Gestational Age |
| Q58572561 | IgG Glyco-Engineering to Improve IVIg Potency |
| Q98177698 | IgG Suppresses Antibody Responses to Sheep Red Blood Cells in Double Knock-Out Mice Lacking Complement Factor C3 and Activating Fcγ-Receptors |
| Q64118813 | IgG and Fcγ Receptors in Intestinal Immunity and Inflammation |
| Q88445153 | IgG and leukocytes: Targets of immunomodulatory α2,6 sialic acids |
| Q33378924 | IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions |
| Q40108236 | IgG subclass and vaccination stimulus determine changes in antigen specific antibody glycosylation in mice. |
| Q34368678 | IgG subclasses and allotypes: from structure to effector functions |
| Q34036447 | IgG transmitted from allergic mothers decreases allergic sensitization in breastfed offspring. |
| Q38115691 | IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease |
| Q38013479 | IgG-Fc glycoengineering in non-mammalian expression hosts |
| Q36213225 | IgG4 can induce an M2-like phenotype in human monocyte-derived macrophages through FcγRI. |
| Q28512966 | Immune complexes regulate bone metabolism through FcRγ signalling |
| Q55094703 | Immune modulation of i.v. immunoglobulin in women with reproductive failure. |
| Q28069362 | Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies |
| Q33381036 | Immune regulation by B cells and antibodies a view towards the clinic. |
| Q34468348 | Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes |
| Q55055409 | Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. |
| Q86421496 | Immunoglobulin G Fc N-glycosylation in Guillain-Barré syndrome treated with intravenous immunoglobulin |
| Q55290367 | Immunoglobulin G Fragment Crystallizable Glycosylation After Hematopoietic Stem Cell Transplantation Is Dissimilar to Donor Profiles. |
| Q33518916 | Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study |
| Q27681704 | Immunoglobulin G1 Fc Domain Motions: Implications for Fc Engineering |
| Q38994739 | Immunoglobulin Glycosylation Effects in Allergy and Immunity |
| Q58861272 | Immunoglobulines intraveineuses dans les maladies auto-immunes et inflammatoires : au-delà d’une simple substitution |
| Q64091767 | Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity |
| Q34289043 | Immunological challenges of cardiac transplantation: the need for better animal models to answer current clinical questions |
| Q42920927 | Immunological intervention in human diseases |
| Q88650321 | Immunological responses to influenza vaccination: lessons for improving vaccine efficacy |
| Q64928515 | Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim? |
| Q33393823 | Immunomodulatory drugs and their application to the management of canine immune-mediated disease |
| Q33576327 | Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies |
| Q24634395 | Immunotherapy of systemic sclerosis |
| Q92613729 | Impact of Fc N-glycan sialylation on IgG structure |
| Q38818688 | Impact of Glycosylation on Effector Functions of Therapeutic IgG |
| Q38762019 | Impact of IgG Fc-Oligosaccharides on Recombinant Monoclonal Antibody Structure, Stability, Safety, and Efficacy. |
| Q97883509 | Impact of Plasma Membrane Domains on IgG Fc Receptor Function |
| Q90535599 | Impact of cell culture media additives on IgG glycosylation produced in Chinese hamster ovary cells |
| Q37140095 | Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy |
| Q48134110 | Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies. |
| Q37342888 | Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma |
| Q39279968 | Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering. |
| Q59132146 | Improving Immunotherapy Through Glycodesign |
| Q40602343 | In planta protein sialylation through overexpression of the respective mammalian pathway |
| Q28547176 | In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity |
| Q38202547 | In vivo kinetics and biodistribution analysis of neoglycoproteins: effects of chemically introduced glycans on proteins |
| Q40114596 | In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques |
| Q82908543 | In vivo veritas: the surprising roles of Fc receptors in immunity |
| Q41880662 | In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap |
| Q27485310 | Increased Levels of Galactose-Deficient Anti-Gal Immunoglobulin G in the Sera of Hepatitis C Virus-Infected Individuals with Fibrosis and Cirrhosis |
| Q34208137 | Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential |
| Q58861264 | Indications et mécanismes d’action des immunoglobulines intraveineuses dans les pathologies auto-immunes et inflammatoires systémiques |
| Q26781290 | Induction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate Immunity |
| Q27010099 | Infection, inflammation and host carbohydrates: a Glyco-Evasion Hypothesis |
| Q37754703 | Inflammation and arthritis: perspectives of the glycobiologist |
| Q35670608 | Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome |
| Q26796413 | Inflammatory etiopathogenesis of systemic lupus erythematosus: an update |
| Q64925019 | Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. |
| Q64253803 | Insertion of N-Terminal Hinge Glycosylation Enhances Interactions of the Fc Region of Human IgG1 Monomers with Glycan-Dependent Receptors and Blocks Hemagglutination by the Influenza Virus |
| Q51081577 | Integrated Genome and Protein Editing Swaps α-2,6 Sialylation for α-2,3 Sialic Acid on Recombinant Antibodies from CHO. |
| Q54977678 | Integration of genetic and metabolic features related to sialic acid metabolism distinguishes human breast cell subtypes. |
| Q37679918 | Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance |
| Q84979117 | Intramolecular Glycan–Protein Interactions in Glycoproteins |
| Q38346284 | Intravenous Immunoglobulin and Immunomodulation of B-Cell - in vitro and in vivo Effects |
| Q22241424 | Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease |
| Q36959840 | Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. |
| Q33270749 | Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study |
| Q27000371 | Intravenous immunoglobulin and Alzheimer's disease: what now? |
| Q33420267 | Intravenous immunoglobulin as clinical immune-modulating therapy |
| Q38308436 | Intravenous immunoglobulin in neurology--mode of action and clinical efficacy |
| Q36302368 | Intravenous immunoglobulin in the management of lupus nephritis. |
| Q37487547 | Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways |
| Q86017374 | Intravenous immunoglobulin replacement therapy in common variable immunodeficiency induces B cell depletion through differentiation into apoptosis-prone CD21(low) B cells |
| Q37573529 | Intravenous immunoglobulin therapy for autoimmune diseases |
| Q37873722 | Intravenous immunoglobulin therapy in rheumatic diseases |
| Q33405903 | Intravenous immunoglobulin therapy: how does IgG modulate the immune system? |
| Q37773248 | Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science |
| Q37732919 | Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients |
| Q38133405 | Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute |
| Q36757383 | Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. |
| Q38304255 | Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future |
| Q37578120 | Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside |
| Q36384725 | Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. |
| Q37626118 | Intravenous immunoglobulins--understanding properties and mechanisms |
| Q39933128 | Intravenous immunoglobulins. Current understanding and future directions. |
| Q35965959 | Investigation of early and advanced stages in ovarian cancer using human plasma by differential scanning calorimetry and mass spectrometry |
| Q37774870 | Involvement of aberrant glycosylation in thyroid cancer |
| Q35951417 | Isotype-specific glycosylation analysis of mouse IgG by LC-MS. |
| Q42372965 | Kinetics of N-Glycan Release from Human Immunoglobulin G (IgG) by PNGase F: All Glycans Are Not Created Equal |
| Q35167400 | Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies |
| Q27671018 | Lanthanide binding and IgG affinity construct: Potential applications in solution NMR, MRI, and luminescence microscopy |
| Q64266918 | Lectin microarray profiling and monosaccharide analysis of bovine milk immunoglobulin G oligosaccharides during the first 10 days of lactation |
| Q39642938 | Lectin-Based Biosensor Strategy for Electrochemical Assay of Glycan Expression on Living Cancer Cells |
| Q36673623 | Lectins: carbohydrate-specific reagents and biological recognition molecules |
| Q37252443 | Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn |
| Q34574913 | Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. |
| Q81041251 | Long-term administration of IgG2a anti-NK1.1 monoclonal antibody ameliorates lupus-like disease in NZB/W mice in spite of an early worsening induced by an IgG2a-dependent BAFF/BLyS production |
| Q34803358 | Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn |
| Q93379659 | Low prevalence of rheumatoid arthritis among patients with pre-existing type 2 diabetes mellitus |
| Q37578785 | Low-affinity Fcgamma receptors, autoimmunity and infection |
| Q37281976 | MALDI-TOF-MS reveals differential N-linked plasma- and IgG-glycosylation profiles between mothers and their newborns. |
| Q44031303 | MS in the analysis of biosimilars |
| Q99711567 | MS-Based Allotype-Specific Analysis of Polyclonal IgG-Fc N-Glycosylation |
| Q33382862 | Macrophages activated by C-reactive protein through Fc gamma RI transfer suppression of immune thrombocytopenia |
| Q36670335 | Making autoantibodies safe |
| Q37290930 | Mammalian glycosylation in immunity |
| Q33815783 | Mannose receptor interacts with Fc receptors and is critical for the development of crescentic glomerulonephritis in mice |
| Q35771248 | Mass spectrometric analysis of products of metabolic glycan engineering with azido-modification of sialic acids. |
| Q35108694 | Mass spectrometric determination of IgG subclass-specific glycosylation profiles in siblings discordant for myositis syndromes |
| Q34247694 | Mass spectrometry in the analysis of N-linked and O-linked glycans |
| Q79375472 | Massive gastrointestinal haemorrhage in isolated intestinal Henoch-Schonlein purpura with response to intravenous immunoglobulin infusion |
| Q42375731 | Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action? |
| Q36260924 | Maternal Pre-Pregnancy Obesity Is Associated with Altered Placental Transcriptome |
| Q38161574 | Mechanisms and potential therapeutic targets in allergic inflammation: recent insights. |
| Q33740580 | Mechanisms of Autoantibody-Induced Pathology. |
| Q37737994 | Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. |
| Q38335199 | Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects |
| Q39119704 | Mechanisms of action of intravenous immunoglobulin |
| Q33389428 | Mechanisms of action of intravenous immunoglobulins |
| Q30371304 | Mechanisms of tolerance induction in allergic disease: integrating current and emerging concepts. |
| Q35292040 | Membrane adsorbers comprising grafted glycopolymers for targeted lectin binding |
| Q41940868 | Mgat2 ablation in the myeloid lineage leads to defective glycoantigen T cell responses |
| Q36821157 | Microarrays in infection and immunity |
| Q50237001 | Microheterogeneity of Recombinant Antibodies: Analytics and Functional Impact |
| Q37558341 | Microscale Measurements of Michaelis-Menten Constants of Neuraminidase with Nanogel Capillary Electrophoresis for the Determination of the Sialic Acid Linkage |
| Q93052135 | Minimal B Cell Extrinsic IgG Glycan Modifications of Pro- and Anti-Inflammatory IgG Preparations in vivo |
| Q90608974 | Model-Driven Engineering of N-Linked Glycosylation in Chinese Hamster Ovary Cells |
| Q41677985 | Modulating IgG effector function by Fc glycan engineering. |
| Q37860624 | Modulation of antibody effector function |
| Q39590627 | Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose |
| Q51749017 | Modulation of mAb quality attributes using microliter scale fed-batch cultures. |
| Q39062945 | Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy |
| Q37511739 | Molecular analysis of an alternative N-glycosylation machinery by functional transfer from Actinobacillus pleuropneumoniae to Escherichia coli. |
| Q59047780 | Molecular and Cellular Pathways of Immunoglobulin G Activity In Vivo |
| Q38135285 | Molecular basis for downregulation of C5a-mediated inflammation by IgG1 immune complexes in allergy and asthma |
| Q26825548 | Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases |
| Q36922576 | Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases |
| Q24655389 | Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization |
| Q37181031 | Monoclonal antibodies for cancer immunotherapy |
| Q35866472 | Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants |
| Q63362959 | Multi-isotype Glycoproteomic Characterization of Serum Antibody Heavy Chains Reveals Isotype- and Subclass-Specific -Glycosylation Profiles |
| Q34270155 | Multifarious roles of sialic acids in immunity |
| Q28390264 | Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants |
| Q58761454 | Multiple Roles of Glycans in Hematological Malignancies |
| Q35747533 | Multiple mechanisms of immune suppression by B lymphocytes |
| Q40054832 | Multivariate discovery and replication of five novel loci associated with Immunoglobulin G N-glycosylation |
| Q37484223 | Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG |
| Q36133312 | N-glycan PK Profiling Using a High Sensitivity nanoLCMS Work-Flow with Heavy Stable Isotope Labeled Internal Standard and Application to a Preclinical Study of an IgG1 Biopharmaceutical |
| Q42973099 | N-linked glycosylation selectively regulates autonomous precursor BCR function |
| Q36249961 | NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation |
| Q50497045 | Nanoscale reversed-phase liquid chromatography-mass spectrometry of permethylated N-glycans. |
| Q37895956 | Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity |
| Q36797342 | Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity |
| Q35170050 | Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model |
| Q94701607 | Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita |
| Q40130027 | Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists |
| Q92133744 | Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity |
| Q39320387 | New Insights into Pericarditis: Mechanisms of Injury and Therapeutic Targets |
| Q41173378 | New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins |
| Q27652073 | New insights into intra- and intermolecular interactions of immunoglobulins: crystal structure of mouse IgG2b-Fc at 2·1-Å resolution |
| Q33900595 | New paradigms for functional HIV-specific nonneutralizing antibodies |
| Q41042837 | Noninvasive Imaging of Dendrimer‐Type N‐Glycan Clusters: In Vivo Dynamics Dependence on Oligosaccharide Structure |
| Q37409360 | Nonredundant roles for B cell-derived IL-10 in immune counter-regulation |
| Q52608527 | Novel Concepts of Altered Immunoglobulin G Galactosylation in Autoimmune Diseases. |
| Q35075181 | Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins |
| Q34307304 | Novel data analysis tool for semiquantitative LC-MS-MS2 profiling of N-glycans |
| Q37979848 | Novel roles for the IgG Fc glycan |
| Q37290692 | Novel targets for immunotherapy in glomerulonephritis |
| Q90736495 | On enzymatic remodeling of IgG glycosylation; unique tools with broad applications |
| Q34253508 | On the perplexingly low rate of transport of IgG2 across the human placenta |
| Q48987144 | One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates |
| Q52547591 | One-pot enzymatic glycan remodeling of a therapeutic monoclonal antibody by endoglycosidase S (Endo-S) from Streptococcus pyogenes. |
| Q37113941 | Opportunities to exploit non-neutralizing HIV-specific antibody activity |
| Q28831266 | Optimal Synthetic Glycosylation of a Therapeutic Antibody |
| Q28831364 | Optimal Synthetic Glycosylation of a Therapeutic Antibody |
| Q90649263 | Overview of the role of kinetoplastid surface carbohydrates in infection and host cell invasion: prospects for therapeutic intervention |
| Q33926907 | Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis |
| Q42846834 | Perioperative Infliximab Application Ameliorates Acute Rejection Associated Inflammation After Intestinal Transplantation |
| Q60956631 | Perspective on the Development and Validation of Ab Reagents to Fish Immune Proteins for the Correct Assessment of Immune Function |
| Q42118646 | Pharmacokinetics of Monoclonal Antibodies. |
| Q34080417 | Physicochemical and biological characterization of 1E10 anti-idiotype vaccine. |
| Q42113781 | Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab). |
| Q34275537 | Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics |
| Q40078229 | Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity. |
| Q36808629 | Polarized immune responses differentially regulate cancer development |
| Q36620451 | Post-translational modifications in the context of therapeutic proteins |
| Q38246996 | Post-translational structural modifications of immunoglobulin G and their effect on biological activity |
| Q55250588 | Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways. |
| Q47132349 | Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins |
| Q35873009 | Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid |
| Q36571261 | Production and characterization of mouse monoclonal antibodies recognizing multiple subclasses of human IgG. |
| Q46250133 | Production of IgGs with a human-like sialylation in CHO cells. |
| Q36213335 | Production of α2,6-sialylated IgG1 in CHO cells |
| Q38408253 | Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis |
| Q43125937 | Profile of Jeffrey Ravetch. Interview by Philip Downey |
| Q46608396 | Profiling N-linked oligosaccharides from IgG by high-performance anion-exchange chromatography with pulsed amperometric detection |
| Q63443148 | Profiling and genetic control of the murine immunoglobulin G glycome |
| Q91844287 | Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential |
| Q55491567 | Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease. |
| Q35262648 | Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D. |
| Q36592223 | Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation. |
| Q35590264 | Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs |
| Q38593866 | Protective role of mouse IgG1 in cryoglobulinaemia; insights from an animal model and relevance to human pathology. |
| Q98466487 | Protein Glycoengineering: An Approach for Improving Protein Properties |
| Q58861270 | Protein destabilizing agents induce polyreactivity and enhanced immunomodulatory activity in IVIg preparations |
| Q37168156 | Protein-glycan interactions in the control of innate and adaptive immune responses |
| Q42748675 | Proteolytic shedding of ST6Gal-I by BACE1 regulates the glycosylation and function of alpha4beta1 integrins |
| Q33934663 | Puzzling inefficiency of H5N1 influenza vaccines in Egyptian poultry |
| Q37999739 | Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach |
| Q35232337 | Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies |
| Q33378989 | Rapid platelet turnover in WASP(-) mice correlates with increased ex vivo phagocytosis of opsonized WASP(-) platelets |
| Q33379309 | Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. |
| Q38050998 | Recent advances in technology supporting biopharmaceutical production from mammalian cells |
| Q92837603 | Recognition of the human antibody-mediated platelet destruction in adult ITP patients by C-reactive protein |
| Q42144247 | Regulation of B cell functions by the sialic acid-binding receptors siglec-G and CD22. |
| Q38957490 | Regulation of antibody effector functions through IgG Fc N-glycosylation |
| Q37877263 | Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation |
| Q51774594 | Regulation of leukocyte recruitment by the long pentraxin PTX3. |
| Q27015093 | Regulatory B cells: an exciting target for future therapeutics in transplantation |
| Q38233691 | Regulatory functions of B cells in allergic diseases |
| Q40223873 | Repeat application of microneedles does not alter skin appearance or barrier function and causes no measurable disturbance of serum biomarkers of infection, inflammation or immunity in mice in vivo. |
| Q46364522 | Reply to Bayry et al.: The anti-inflammatory activity of sialylated IgG Fcs. |
| Q42971141 | Reply to Crispin et al.: Molecular model that accounts for the biological and physical properties of sialylated Fc. |
| Q57253422 | Reply to — IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist |
| Q37778732 | Research and development of next generation of antibody-based therapeutics |
| Q34315442 | Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient FcγRIIIa binding |
| Q34555935 | Reversibility of membrane N-glycome of HeLa cells upon treatment with epigenetic inhibitors |
| Q38258905 | Review: intravenous immunoglobulin and B cells: when the product regulates the producer |
| Q40461706 | Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection. |
| Q34724042 | Role of glycosylation in structure and stability of Erythrina corallodendron lectin (EcorL): a molecular dynamics study |
| Q36739762 | Role of monoclonal antibodies in tumor-specific immunity |
| Q57253408 | Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation |
| Q35164415 | Role of siglecs and related glycan-binding proteins in immune responses and immunoregulation |
| Q49972870 | SHIP negatively regulates type II immune responses in mast cells and macrophages |
| Q42917889 | Self and nonself recognition with bacterial and animal glycans, surveys by synthetic chemistry |
| Q46360891 | Separation of nonfucosylated antibodies with immobilized FcγRIII receptors |
| Q45999306 | Serum glycosylation characterization of osteonecrosis of the femoral head by mass spectrometry. |
| Q58864656 | Shortage of human intravenous immunoglobulin—reasons and possible solutions |
| Q38283308 | Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered? |
| Q37586575 | Sialic acid level reflects the disturbances of glycosylation and acute-phase reaction in rheumatic diseases |
| Q48726112 | Sialic acid linkage-specific permethylation for improved profiling of protein glycosylation by MALDI-TOF MS. |
| Q41888076 | Sialic acid on herpes simplex virus type 1 envelope glycoproteins is required for efficient infection of cells |
| Q43789293 | Sialidase inhibitors attenuate pulmonary fibrosis in a mouse model |
| Q55347406 | Sialylated Autoantigen-Reactive IgG Antibodies Attenuate Disease Development in Autoimmune Mouse Models of Lupus Nephritis and Rheumatoid Arthritis. |
| Q48210931 | Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy |
| Q37085836 | Sialylated immunoglobulin G can neutralize influenza virus infection through receptor mimicry |
| Q42316355 | Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury |
| Q51370563 | Sialylation and desialylation dynamics of monocytes upon differentiation and polarization to macrophages. |
| Q90171001 | Sialylation and fucosylation modulate inflammasome-activating eIF2 Signaling and microbial translocation during HIV infection |
| Q36768842 | Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis. |
| Q36352180 | Sialylation determines the nephritogenicity of IgG3 cryoglobulins |
| Q58004245 | Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's) |
| Q36266469 | Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity |
| Q57253368 | Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells |
| Q33399238 | Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. |
| Q35959088 | Sialyltransferase and Neuraminidase Levels/Ratios and Sialic Acid Levels in Peripheral Blood B Cells Correlate with Measures of Disease Activity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Pilot Study |
| Q58612152 | Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody |
| Q37117619 | Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag |
| Q53081892 | Site-specific immobilization of endoglycosidases for streamlined chemoenzymatic glycan remodeling of antibodies. |
| Q35158352 | Site-specific modification of ED-B-targeting antibody using intein-fusion technology |
| Q92173365 | Small-molecule control of antibody N-glycosylation in engineered mammalian cells |
| Q47286747 | Solid-Phase Enzymatic Remodeling Produces High Yields of Single Glycoform Antibodies |
| Q47110972 | Spoiling for a Fight: B Lymphocytes As Initiator and Effector Populations within Tertiary Lymphoid Organs in Autoimmunity and Transplantation. |
| Q63433108 | Streptococcal Endo-β--Acetylglucosaminidase Suppresses Antibody-Mediated Inflammation |
| Q27684721 | Structural Characterization of Anti-Inflammatory Immunoglobulin G Fc Proteins |
| Q38615376 | Structural analysis of Fc/FcγR complexes: a blueprint for antibody design. |
| Q26824272 | Structural and functional characteristics of bovine milk protein glycosylation |
| Q34619043 | Structural and functional characterization of the trifunctional antibody catumaxomab |
| Q27675205 | Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans |
| Q47846522 | Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody |
| Q36624176 | Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa |
| Q38615372 | Structural mechanism of high affinity FcγRI recognition of immunoglobulin G. |
| Q35031336 | Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. |
| Q89473460 | Structure-function relationships of the soluble form of the antiaging protein Klotho have therapeutic implications for managing kidney disease |
| Q42364603 | Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health |
| Q34107337 | Substrate specificity of cytoplasmic N-glycosyltransferase |
| Q50193260 | Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation |
| Q38239288 | Sweet and sour: the role of glycosylation for the anti-inflammatory activity of immunoglobulin G. |
| Q38851112 | Sweet but dangerous - the role of immunoglobulin G glycosylation in autoimmunity and inflammation. |
| Q33414406 | Sweetened antibodies against humoral autoimmunity: sialylated antibodies are required for IVIg-mediated therapy |
| Q33265617 | Synthetic antibodies as therapeutics |
| Q37123859 | T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. |
| Q91838076 | TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes |
| Q55234556 | Targeting B Cells and Plasma Cells in Autoimmune Diseases. |
| Q38207937 | Targeting B cells and autoantibodies in the therapy of autoimmune diseases |
| Q33758483 | Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice. |
| Q52370705 | Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues. |
| Q27002843 | Targeting the Fc receptor in autoimmune disease |
| Q36516810 | The "sweet" side of a long pentraxin: how glycosylation affects PTX3 functions in innate immunity and inflammation |
| Q37206320 | The Association Between Glycosylation of Immunoglobulin G and Hypertension: A Multiple Ethnic Cross-Sectional Study |
| Q95513710 | The Author Replies |
| Q50129712 | The B cell response to citrullinated antigens in the development of rheumatoid arthritis. |
| Q60047547 | The Clinical Value of Autoantibodies in Rheumatoid Arthritis |
| Q92921343 | The Contribution of IgG Glycosylation to Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC) in Hashimoto's Thyroiditis: An in Vitro Model of Thyroid Autoimmunity |
| Q33430624 | The Elements Steering Pathogenesis in IgG-Mediated Alloimmune Diseases |
| Q38724772 | The Emerging Importance of IgG Fab Glycosylation in Immunity. |
| Q88669457 | The Glycoscience of Immunity |
| Q37293581 | The Golgi CMP-sialic acid transporter: A new CHO mutant provides functional insights |
| Q33931736 | The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis |
| Q90460486 | The Impact of Immunoglobulin G1 Fc Sialylation on Backbone Amide H/D Exchange |
| Q33740762 | The N-Glycosylation of Mouse Immunoglobulin G (IgG)-Fragment Crystallizable Differs Between IgG Subclasses and Strains |
| Q35818105 | The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation |
| Q59360845 | The Potential Role of Fc-Receptor Functions in the Development of a Universal Influenza Vaccine |
| Q39088502 | The Role and Function of Fcγ Receptors on Myeloid Cells |
| Q57019841 | The Role of Fc Gamma Receptors in Broad Protection against Influenza Viruses |
| Q28395318 | The Role of Posttranslational Protein Modifications in Rheumatological Diseases: Focus on Rheumatoid Arthritis |
| Q36021825 | The Structural Role of Antibody N-Glycosylation in Receptor Interactions |
| Q38066414 | The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade |
| Q24676548 | The antiinflammatory activity of IgG: the intravenous IgG paradox |
| Q64926950 | The association between subclass-specific IgG Fc N-glycosylation profiles and hypertension in the Uygur, Kazak, Kirgiz, and Tajik populations. |
| Q38117686 | The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies |
| Q37091308 | The case for immunomodulatory approaches in treating HSV encephalitis |
| Q37638949 | The challenge and promise of glycomics |
| Q36213158 | The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development |
| Q38182645 | The expanding role of therapeutic antibodies |
| Q37027166 | The growth and potential of human antiviral monoclonal antibody therapeutics. |
| Q90027632 | The history of IgG glycosylation and where we are now |
| Q42116482 | The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor |
| Q36670313 | The impact of microcarrier culture optimization on the glycosylation profile of a monoclonal antibody |
| Q36976399 | The isotype repertoire of antibodies against novel UH-RA peptides in rheumatoid arthritis. |
| Q36819920 | The mast cell IgG receptors and their roles in tissue inflammation |
| Q38615385 | The multiple facets of FcRn in immunity. |
| Q37664865 | The other side of immunoglobulin G: suppressor of inflammation |
| Q38206946 | The pathogenic potential of autoreactive antibodies in rheumatoid arthritis. |
| Q38824186 | The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking? |
| Q38268922 | The protective role of immunoglobulins in fungal infections and inflammation |
| Q36906422 | The regulatory power of glycans and their binding partners in immunity |
| Q28075279 | The role of genetics and antibodies in sepsis |
| Q38218832 | The role of glycosylation in IBD. |
| Q37995919 | The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. |
| Q38029304 | The sweet tooth of biopharmaceuticals: importance of recombinant protein glycosylation analysis. |
| Q94452368 | The trinity of COVID-19: immunity, inflammation and intervention |
| Q41170285 | Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury |
| Q38149195 | Therapeutic antibodies as a treatment option for dengue fever |
| Q39729881 | Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. |
| Q36950457 | Therapeutic potential of deglycosylated antibodies. |
| Q37807782 | Therapeutic use of immunoglobulins |
| Q37780677 | Tolerance: an overview and perspectives |
| Q42687289 | Total synthesis of the 2,6-sialylated immunoglobulin G glycopeptide fragment in homogeneous form. |
| Q30419992 | Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress |
| Q92229013 | Transcriptome alteration spectrum in rat lung induced by radiotherapy |
| Q40762677 | Translating Inhibitory Fc Receptor Biology into Novel Therapeutic Approaches |
| Q26991899 | Translating basic mechanisms of IgG effector activity into next generation cancer therapies |
| Q41967328 | Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step |
| Q37557375 | Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations. |
| Q53816522 | Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution? |
| Q26822442 | Treatment of spinal cord injury with intravenous immunoglobulin G: preliminary evidence and future perspectives |
| Q37974990 | Treatment of systemic lupus erythematosus: new advances in targeted therapy |
| Q35063963 | Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G |
| Q57640701 | Treatment with Low Doses of Polyclonal Immunoglobulin Improves B Cell Function During Immune Reconstitution in a Murine Model |
| Q36781300 | Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORγt and Ahr that leads to IL-17 production by activated B cells |
| Q38232105 | Type I and type II Fc receptors regulate innate and adaptive immunity |
| Q30394129 | Ubiquitous Importance of Protein Glycosylation |
| Q89901292 | Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases |
| Q93078490 | Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections |
| Q27670877 | Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose |
| Q36253487 | Unusual transglycosylation activity of Flavobacterium meningosepticum endoglycosidases enables convergent chemoenzymatic synthesis of core fucosylated complex N-glycopeptides |
| Q36632113 | Use of mouse models to study the mechanisms and consequences of RBC clearance. |
| Q38547311 | Using glyco-engineering to produce therapeutic proteins. |
| Q91694478 | Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer |
| Q55091658 | Variable Domain N-Linked Glycans Acquired During Antigen-Specific Immune Responses Can Contribute to Immunoglobulin G Antibody Stability. |
| Q35656099 | Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections |
| Q39067348 | Will sialylation change intravenous immunoglobulin therapy in the future? |
| Q38055447 | With or without sugar? (A)glycosylation of therapeutic antibodies |
| Q85397964 | [Glycosylation-dependent effector function of IgG antibodies] |
| Q45964401 | [Optimizing therapy in patients with severe autoimmune blistering skin diseases]. |
| Q83179107 | [The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies] |
| Q54102494 | [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders]. |
| Q38615353 | bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression. |
Search more.